Skip to main content
Journal cover image

Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study.

Publication ,  Journal Article
Chiarito, M; Cao, D; Sartori, S; Zhang, Z; Vogel, B; Spirito, A; Smith, KF; Weintraub, W; Strauss, C; Toma, C; DeFranco, A; Effron, MB ...
Published in: Eur Heart J Acute Cardiovasc Care
September 25, 2023

AIMS: Based on recent clinical data, the 2020 ESC guidelines on non-ST-elevation acute coronary syndrome (NSTE-ACS) suggest to tailor antithrombotic strategy on individual thrombotic risk. Nonetheless, prevalence and prognostic impact of the high thrombotic risk (HTR) criteria proposed are yet to be described. In this analysis from the PROMETHEUS registry, we assessed prevalence and prognostic impact of HTR, defined according to the 2020 ESC NSTE-ACS guidelines, and if the benefits associated with prasugrel vs. clopidogrel vary with thrombotic risk. METHODS AND RESULTS: PROMETHEUS was a multicentre prospective study comparing prasugrel vs. clopidogrel in ACS patients undergoing percutaneous coronary intervention (PCI). Patients were at HTR if presenting with one clinical plus one procedural risk feature. The primary endpoint was major adverse cardiac events (MACE), composite of death, myocardial infarction, stroke, or unplanned revascularization, at 1 year. Adjusted hazard ratio (adjHR) and 95% confidence intervals (CIs) were calculated with propensity score stratification and multivariable Cox regression. Among 16 065 patients, 4293 (26.7%) were at HTR and 11 772 (73.3%) at low-to-moderate thrombotic risk. The HTR conferred increased incidence of MACE (23.3 vs. 13.6%, HR 1.85, 95% CI 1.71-2.00, P < 0.001) and its single components. Prasugrel was prescribed in patients with less comorbidities and risk factors and was associated with reduced risk of MACE (HTR: adjHR 0.83, 95% CI 0.68-1.02; low-to-moderate risk: adjHR 0.75, 95% CI 0.64-0.88; pinteraction = 0.32). CONCLUSION: High thrombotic risk, as defined by the 2020 ESC NSTE-ACS guidelines, is highly prevalent among ACS patients undergoing PCI. The HTR definition had a strong prognostic impact, as it successfully identified patients at increased 1 year risk of ischaemic events.

Duke Scholars

Published In

Eur Heart J Acute Cardiovasc Care

DOI

EISSN

2048-8734

Publication Date

September 25, 2023

Volume

12

Issue

9

Start / End Page

594 / 603

Location

England

Related Subject Headings

  • Treatment Outcome
  • Thrombosis
  • Prospective Studies
  • Prasugrel Hydrochloride
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Patient Discharge
  • Humans
  • Clopidogrel
  • Acute Coronary Syndrome
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chiarito, M., Cao, D., Sartori, S., Zhang, Z., Vogel, B., Spirito, A., … Mehran, R. (2023). Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study. Eur Heart J Acute Cardiovasc Care, 12(9), 594–603. https://doi.org/10.1093/ehjacc/zuad083
Chiarito, Mauro, Davide Cao, Samantha Sartori, Zhongjie Zhang, Birgit Vogel, Alessandro Spirito, Kenneth F. Smith, et al. “Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study.Eur Heart J Acute Cardiovasc Care 12, no. 9 (September 25, 2023): 594–603. https://doi.org/10.1093/ehjacc/zuad083.
Chiarito M, Cao D, Sartori S, Zhang Z, Vogel B, Spirito A, et al. Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study. Eur Heart J Acute Cardiovasc Care. 2023 Sep 25;12(9):594–603.
Chiarito, Mauro, et al. “Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study.Eur Heart J Acute Cardiovasc Care, vol. 12, no. 9, Sept. 2023, pp. 594–603. Pubmed, doi:10.1093/ehjacc/zuad083.
Chiarito M, Cao D, Sartori S, Zhang Z, Vogel B, Spirito A, Smith KF, Weintraub W, Strauss C, Toma C, DeFranco A, Effron MB, Stefanini G, Keller S, Kapadia S, Rao SV, Henry TD, Pocock S, Sharma S, Dangas G, Kini A, Baber U, Mehran R. Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study. Eur Heart J Acute Cardiovasc Care. 2023 Sep 25;12(9):594–603.
Journal cover image

Published In

Eur Heart J Acute Cardiovasc Care

DOI

EISSN

2048-8734

Publication Date

September 25, 2023

Volume

12

Issue

9

Start / End Page

594 / 603

Location

England

Related Subject Headings

  • Treatment Outcome
  • Thrombosis
  • Prospective Studies
  • Prasugrel Hydrochloride
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Patient Discharge
  • Humans
  • Clopidogrel
  • Acute Coronary Syndrome